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Summary
Background: When used proactively, drug-tolerant anti-tumour necrosis factor (TNF) 
antibody assays provide early opportunity to suppress immunogenicity.
Aim: To validate positivity thresholds of IDKmonitor drug-tolerant anti-infliximab and 
-adalimumab antibody assays.
Methods: We applied positivity thresholds, defined by testing sera from 498 anti-TNF 
naive healthy adults, from the Exeter Ten Thousand study to data from our therapeutic 
drug monitoring (TDM) service and Personalised Anti-TNF Therapy in Crohn's disease 
(PANTS) cohort to explore associations with drug level and treatment outcomes.
Results: The 80% one-sided lower confidence interval of the 99th centile concentra-
tion for anti-infliximab and –adalimumab antibodies were lower than the manufac-
turers threshold of 10 arbitrary units (AU)/mL; 9 and 6 AU/mL, respectively. Using 
these new thresholds in the TDM cohort, more adalimumab- than infliximab- (11.2% 
[814/7272] vs 3.1% [390/12 683] P < 0.0001) treated patients were reclassified 
as antibody-positive. Adalimumab drug concentrations in this reclassified group 
 (median 8.1, interquartile range [IQR] 5.5-11.0 mg/L) were lower than those below 
the new threshold (≤5AU/mL) (median 9.9, IQR 7.1-13.0 mg/L; P < 0.0001), but higher 
than at the manufacturer's threshold (10-29 AU/mL) (median 5.9 mg/L, IQR 3.5-8.7; 
P < 0.0001). No difference in infliximab drug concentration was observed using the 
new or manufacturer's positivity threshold (P = 0.11). In the PANTS cohort, patients 
with anti-adalimumab antibody concentrations at or above the new threshold were 
more likely to be in primary non-response (25/68 [37%] vs. 64/332 [19%], P = 0.0035), 
and non-remission at week 54 (51/62 [82%] vs. 168/279 [60%], P = 0.0011), than pa-
tients with anti-drug antibody concentrations in the group below the new threshold 
(0-5 AU/mL); this was not seen for anti-infliximab antibodies.
Conclusion: Laboratories should derive antibody positivity thresholds for assays they 
use. For adalimumab, low-concentration anti-drug antibodies were associated with 
lower drug levels and treatment failure.
This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
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1  | INTRODUC TION
Biopharmaceuticals, or biologics, are large complex proteins manu-
factured in, or derived from, living sources. The anti-tumour necro-
sis factor (TNF) therapies, infliximab and adalimumab, are the most 
widely used biologics for treating immune-mediated diseases, in-
cluding inflammatory bowel disease, and in 2018, they accounted for 
an expenditure in excess of $29 billion in the United States alone.1 
Repeated administration, however, often induces the formation 
of anti-drug antibodies that lead to drug clearance and treatment 
failure.2-5
Pharmacokinetic therapeutic drug monitoring (TDM) in patients 
with inflammatory bowel disease, improves durability of response, 
safety and cost-effectiveness of anti-TNF therapy, compared to 
empirical dosing alone.6-9 Debate remains, however, how best to 
measure drug and anti-drug antibody levels and whether TDM is 
best undertaken proactively during routine follow-up, or whether 
reactive TDM at the time of loss of response is adequate.10 Recent 
data support proactive TDM because it allows optimisation of drug 
levels and earlier detection of anti-drug antibodies, which provides a 
window of opportunity for clinicians to suppress immunogenicity by 
introducing an immunomodulator.9,11-16
Enzyme-linked immunosorbent assays (ELISAs) are the most 
commonly used analytical methods for the measurement of an-
ti-TNF drug and anti-drug antibody levels.17,18 Most studies have 
reported results using ‘drug-sensitive’ or ‘free’ antibody assays. 
‘Drug-tolerant’ or ‘total’ antibody assays include a pre-analytical 
acid antibody-drug disassociation step. This allows antibodies to 
be detected earlier, at a potentially reversible stage, when drug is 
still present. These assays are therefore ideally suited for proac-
tive TDM.17
The Academic Department of Blood Sciences at the Royal Devon 
and Exeter NHS Foundation Trust uses the Immundiagnostik AG 
(IDKmonitor) drug-tolerant anti-infliximab and anti-adalimumab an-
tibody assays for its national TDM service. The positivity threshold 
is defined by the manufacturer as 10 arbitrary units (AU)/mL. We 
sought to validate this positivity threshold for both assays and to de-
scribe the relationship between drug and anti-drug antibody levels 
and clinical outcomes using these new positivity thresholds.
2  | METHODS
2.1 | Study design
We designed three related studies in mutually exclusive cohorts:
• To validate the positivity thresholds of the IDK drug-tolerant 
anti-TNF antibody assays, we tested sera from healthy individu-
als who had not been exposed to anti-TNF therapies (EXTEND 
cohort).
• To explore the relationship between drug and anti-drug antibody 
levels and the impact on clinical reporting at the new positivity 
threshold we used paired drug and antibody data from our TDM 
Clinical Service (Exeter TDM cohort).
• To test whether anti-drug antibody concentrations using the new 
positivity thresholds were associated with treatment failure, we 
reanalysed data from the prospective Personalised Anti-TNF 
Therapy in Crohn's disease study at the new positivity threshold 
(PANTS cohort).
2.2 | Participants and outcome definitions
2.2.1 | Validating the positivity threshold
The Exeter Ten Thousand (EXTEND) cohort is a prospective cohort 
study with a recallable biorepository designed to understand genetic 
contributions to common diseases. To be included, adult volunteers 
needed to live within 25 miles of the city of Exeter in the South 
West of England, United Kingdom (EXTEND; www.exete r10000.
org). Participants were invited to a single 30-minute appointment 
when they completed a short self-reported questionnaire about 
their health and lifestyle and provided urine and blood samples. We 
tested sera from a random sample of 498 healthy volunteers from 
this cohort for antibodies to infliximab and adalimumab, who were 
not taking regular medications and had never been exposed to anti-
TNF therapies. We validated the positivity thresholds as the 80% 
one-sided lower confidence interval of the 99th centile of antibody 
concentration in the EXTEND cohort, as per the United States Food 
and Drug Administration and European Medicines Agency guide-
lines for validating confirmatory assays.19,20
2.2.2 | Exploring the relationship between drug and 
antibody levels
The Academic Department of Blood Sciences at the Royal Devon 
and Exeter NHS Foundation Trust provides an anti-TNF TDM clinical 
service to hospitals throughout the UK. Requests come from physi-
cians who work in a variety of disciplines; the majority are from gas-
troenterologists administering anti-TNF therapy for inflammatory 
bowel disease. Clinicians are asked to send trough drug levels, but 
no clinical data are linked to TDM test requests. We applied the new 
positivity thresholds to anti-infliximab and –adalimumab antibody 
results from the Exeter laboratory TDM cohort.21 We compared 
drug levels in antibody-positive patients using the manufacturer's 
threshold and the new threshold.
In all patients with paired drug and anti-drug antibody results 
at the time of last testing, we assigned the proportion of patients 
who had clearing (antibody positive, drug negative; <0.8 mg/L) and 
non-clearing anti-drug antibodies (antibody positive, drug positive; 
≥0.8 mg/L) using the new thresholds compared to using the manu-
facturers threshold.
In order to explore the effect of lowering the diagnostic positiv-
ity threshold on the prevalence of transient antibodies, in patients 
130  |     NICE Et al.
who had multiple anti-drug antibody tests, we classified the pro-
portion of patients who had consistently negative (all antibody tests 
negative); transient (a single positive test with subsequent negative 
test); single last-test positive (last test positive with no subsequent 
antibody measurements) and persistent (at least two positive tests) 
anti-drug antibodies.
2.2.3 | Investigating antibody positivity and 
treatment failure
PANTS is a UK-wide, multicentre, prospective observational cohort 
reporting the treatment failure rates of the anti-TNF drugs infliximab 
(originator, Remicade [Merck Sharp & Dohme, UK] and biosimilar 
CT-P13 [Celltrion]), and adalimumab (Humira [Abbvie]) in 1610 anti-
TNF naive patients with active luminal Crohn's disease.3 Treatment 
failure endpoints were primary non-response at week 14 and non-
remission at week 54. Primary non-response was defined as exit 
for resectional surgery or corticosteroid use at week 14. Patients 
who exhibited both a failure of C-reactive protein to fall to ≤3 mg/L 
or by 50% from baseline and a failure of Harvey Bradshaw Index22 
to fall to ≤4 or by 3 points were also classified as primary non-re-
sponse. For children, a failure of short Pediatric Crohn's Disease 
Activity Index23 to fall to <15 or by more than 12.5 points was used. 
Response and grey zone were intermediate categories based on im-
provements in symptoms and/or C-reactive protein, respectively 
Remission was defined at week 14 and 54 as a C-reactive protein of 
≤3 mg/L and Harvey Bradshaw Index of ≤4 points (short Pediatric 
Crohn's Disease Activity Index ≤15), without ongoing steroid ther-
apy or exit for treatment failure.
2.3 | Laboratory methods
All laboratory analyses were performed at the Academic Department 
of Blood Sciences at the Royal Devon and Exeter NHS Foundation 
Trust. Anti-TNF drug and anti-drug antibodies were measured on a 
Dynex Technologies (Chantilly, Virginia, USA) DS2 automated ELISA 
platform.
2.4 | Drug-tolerant anti-TNF antibody assays
The Immundiagnostik (IDK) AG (Bensheim, Germany) IDKmonitor 
infliximab (K9654) and adalimumab (K9651) total anti-drug anti-
body assays allow semi-quantitative measurement of both free 
and bound anti-drug antibodies.24,25 A pre-treatment acid dis-
sociation step is used to separate anti-drug antibodies from the 
therapeutic antibody. The assay then follows a standard ELISA 
format using recombinant therapeutic antibody as a capture and 
detection antibody. For both assays, the manufacturer established 
a positivity threshold by linear dilution of sera with high concen-
trations of anti-TNF antibody until no further linear dilution was 
possible; 10 AU/ml for both assays. The manufacturer then vali-
dated the anti-TNF antibody threshold in sera from 40 anti-TNF 
naive individuals.
The infliximab and adalimumab total anti-drug antibody assays 
have measuring ranges of 4.5-400 AU/mL and 5.5-200 AU/mL, re-
spectively. Based on analysis of pooled patient serum quality con-
trol, the intra-assay coefficient of variation is ≤8.7% at 11.8 AU/mL 
for the infliximab total anti-drug antibody assay (n = 128), ≤13.16% 
at 12.7 AU/mL for adalimumab antibodies (n = 130). The manufac-
turer's recommended positivity threshold for both total anti-TNF 
drug antibody assays is 10 AU/mL.
2.5 | Anti-TNF drug level assays
The IDKmonitor free infliximab (K9655) and adalimumab (K9657) 
drug level assays permit quantitative measurement of free therapeu-
tic drug in serum. The assays follow a standard ELISA format using a 
specific monoclonal anti-drug antibody fragment as a capture anti-
body and peroxidase-labelled anti-human IgG antibody as a detec-
tion antibody. The measuring range for both assays is 0.8-45 mg/L, 
with absence of drug being defined using a cut-off of <0.8 mg/L.
2.6 | Statistical analysis
Statistical analyses were undertaken in R version 3.6.3 (R Foundation 
for Statistical Computing). All analyses were two tailed, unless oth-
erwise stated, and P < 0.05 were considered significant. Summary 
descriptive statistics are presented as median and interquartile 
ranges for continuous variables and as percentages for categorical 
variables.
2.7 | Validating the positivity threshold
We constructed cumulative distribution plots of anti-drug antibody 
concentrations from the EXTEND cohort and used bootstrapping to 
calculate the 80% one-sided lower confidence interval of the 99th 
centile to define anti-infliximab and anti-adalimumab antibody assay 
threshold.19,20
2.8 | Exploring the relationship between drug and 
antibody levels
To visualise the relative effects of changing from the manufac-
turer's positivity thresholds to the newly validated thresholds, we 
also constructed cumulative distribution plots of anti-infliximab 
or—adalimumab antibody concentrations in all patients at the 
time of last testing in the Exeter TDM cohort. We used pairwise 
Mann-Whitney U tests to compare median drug concentrations 
in patients with increasing anti-drug antibody concentrations. 
     |  131NICE Et al.
Anti-drug antibody levels for each drug were categorised as fol-
lows: positive using the new positivity threshold, positive using 
the manufacturer's threshold, and based on cut-offs established 
in the PANTS study; moderate and high antibody concentrations 
(30-99 AU/mL and ≥100 AU/mL respectively).3 Differences be-
tween proportions of patients with clearing, non-clearing, tran-
sient and persistent anti-drug antibodies using the manufacturers 
and the newly validated positivity thresholds, were sought using 
chi-squared analyses.
2.9 | Investigating antibody positivity and 
treatment failure
We collapsed the predefined treatment outcomes from the PANTS 
study—grey zone and response, into the remission category at week 
14. We used chi-squared analyses to detect differences in rates of 
primary non-response at week 14 and non-remission at week 54 
between patients with increasing antibody concentrations using the 
categories described above.3
2.10 | Ethical considerations
In line with Health Research Authority guidelines, formal ethics 
approval for our TDM service evaluation was not required.26 The 
sponsor of both the EXTEND and PANTS studies is the Royal Devon 
and Exeter NHS Foundation Trust. The South West Research Ethics 
Committee approved both studies (REC Reference: 14/SW/1089 for 
Exeter 10,000; November 2009, REC Reference: 12/SW/0323 for 
the PANTS study; January 2013). Patients were involved in the de-
sign of both the EXTEND and PANTS cohorts.
3  | RESULTS
3.1 | Defining the positivity threshold
We obtained sera from 498 healthy volunteers who had not been 
exposed to anti-TNF therapies: 54.0% (269/498) were female, 91.4% 
(455/498) were white European, with a median age of 48 (interquar-
tile range [IQR] 39-58) years. Overall, 5.2% (26/498) were current 
smokers. At inclusion 39.4% (196/498) individuals were overweight 
(Body Mass Index 25-29.9 kg/m2) and 14.5% (72/498) were obese 
(Body Mass Index >30 kg/m2).
Cumulative distribution plots for anti-TNF drug concentrations 
in the healthy volunteers from the EXTEND cohort are shown in 
Figure 1A,B. The 80% one-sided lower confidence interval of the 
99th centile concentrations for anti-drug antibodies to infliximab 
and adalimumab were 9 and 6 AU/mL, respectively, both lower than 
the manufacturers recommended threshold of 10 AU/mL (the point 
estimate of the 99% centiles were 10 AU/mL for antibodies to inflix-
imab and 6 AU/mL for antibodies to adalimumab).
3.2 | Exploring the relationship between drug and 
antibody levels
Between January 2012 and December 2019, 32 490 paired inflixi-
mab and 11 830 adalimumab drug and anti-drug antibody assays in 
12 683 and 7272 patients, respectively were analysed as part of the 
routine TDM service in Exeter.
F I G U R E  1   (A and B) Cumulative distribution plots of anti-drug 
antibody concentrations (on a log scale) in 498 biologic-naive 
healthy volunteers using our drug-tolerant anti-infliximab (A) and 
anti-adalimumab (B) assays respectively. The vertical line denotes 
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At the time of last testing, immunogenicity was more common 
in infliximab- than adalimumab-treated patients, irrespective of 
whether we used the manufacturers or the newly validated posi-
tivity threshold (Figure 2A,B). Using the manufacturer's threshold 
of 10 AU/mL, anti-infliximab antibodies were detected in 47.8% 
(6068/12 683) patients compared to 24.4% (1771/7272) adalimum-
ab-treated patients (P < 0.0001). The proportion of patients reclas-
sified as positive with anti-drug antibodies using the newly validated 
positivity thresholds (infliximab 9 AU/mL and adalimumab 6 AU/mL), 
was greater in adalimumab (11.1% [814/7272]) than infliximab (3.1% 
[390/12 683])-treated patients (P < 0.0001). Reducing the positiv-
ity threshold resulted in more patients classified with non-clear-
ing antibodies to both infliximab (manufacturer's threshold 26.7% 
(3390/12 683) vs. newly validated threshold 29.4% (3733/12 683) 
P < 0.0001) and adalimumab (manufacturer's threshold 15.8% 
(1146/7272) vs. newly validated threshold 26.7% (1941/7272) 
P < 0.0001): but had no effect on the proportions of patients with 
clearing antibodies, to either drug (Table 1).
In total, 6170 and 2673 patients had more than one anti-inflix-
imab and anti-adalimumab antibody level tested, respectively. The 
median number of tests per patient was 3 (range: 2-4) for infliximab- 
and 2 (range: 2-3) for adalimumab-treated patients.
Reducing the positivity threshold resulted in more patients being 
classified with persistent anti-drug antibodies to both infliximab 
(manufacturer's threshold 41.3% [2551/6170]) vs. newly validated 
threshold 44.8% [2765/6170] P < 0.0001) and adalimumab (manu-
facturer's threshold 16.5% (440/2673) vs. newly validated threshold 
26.3% (704/2673) P < 0.0001). The proportions of adalimumab-, but 
not infliximab-treated, patients whose last and only anti-drug anti-
body test was positive or who had transient antibodies increased 
following the reclassification of anti-drug antibody test results 
(Table 1).
The effect of progressively increasing anti-drug antibodies 
on infliximab and adalimumab drug concentrations is shown in 
Figure 3A,B, respectively. Adalimumab concentrations in the newly 
reclassified positive group (6-9 AU/mL) were lower (median adali-
mumab concentration 8.1, IQR 5.5-11.0 mg/L), than in the group 
below the new threshold (≤5 AU/mL) (median adalimumab concen-
tration 9.9, IQR 7.1-13.0 mg/L; P < 0.0001) but were not as low as in 
the group above the manufacturer's threshold (10-29 AU/mL) (me-
dian adalimumab concentration 5.9, IQR 3.5-8.7 mg/L; P < 0.0001). 
There was no significant difference between infliximab concentra-
tions for patients with an anti-infliximab concentration of 9 AU/mL 
(the group reclassified with the lowered threshold) and those with an 
anti-infliximab concentration of < 9 AU/mL (P = 0.11).
3.3 | Investigating antibody positivity and 
treatment failure
The difference between the new anti-infliximab antibody positiv-
ity threshold (9 AU/mL) and manufacturer's threshold (10 AU/mL) is 
very small. When applied to the PANTS cohort only 1.7% (11/658) 
infliximab-treated patients would be reclassified as antibody posi-
tive at week 14 compared to 5.7% (24/420) for adalimumab-treated 
patients. In view of the small proportion of infliximab-treated 
F I G U R E  2   (A and B) Cumulative distribution plots of anti-
drug antibody concentrations (log scale) measured by the 
Exeter therapeutic drug monitoring service from January 
2012 to December 2019 from infliximab- (A) n = 12 683 and 
adalimumab- (B) n = 7272 treated patients. Vertical lines indicate 
our newly validated positivity thresholds of 9 and 6 AU/mL for 
infliximab and adalimumab, respectively, and the manufacturer's 
threshold of 10 AU/mL. Samples in pink are those less than the 
newly validated threshold in green are those between the newly 
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patients reclassified as positive in the PANTS cohort, the relation-
ship between antibody positivity and treatment failure has not been 
investigated in this group. Adalimumab-treated patients on combi-
nation therapy with an immunomodulator were less likely to develop 
anti-drug antibodies above our new threshold of 6 AU/mL compared 
to patients on monotherapy with adalimumab only (P < 0.0001; 
Table 2).
Week 14 adalimumab drug concentrations in the reclassified pos-
itive group (6-9 AU/mL), were lower (median 7.6, IQR 6.1-9.1 mg/L) 
than in the group below the new threshold (0-5 AU/mL) (median 
11.5, IQR 8.7-14.8 mg/L, P < 0.0001), but were not as low as individ-
uals above the manufacturer's threshold (10-29 AU/mL) (median 5.8, 
IQR 2.1-8.0 mg/L, P = 0.035; Figure 4).
Using the prespecified outcome definitions from PANTS, at week 
14, patients with anti-adalimumab antibody concentrations at or 
above the new threshold were more likely to be in primary non-re-
sponse (25/68 [37%] vs. 64/332 [19%], P = 0.0035), and non-re-
mission at week 54 (51/62 [82%] vs. 168/279 [60%], P = 0.0011), 
(Figure 5A,B) than patients with anti-drug antibody concentrations 
in the group below the new threshold (0-5 AU/mL).
4  | DISCUSSION
4.1 | Key findings
We have demonstrated that the positivity thresholds for the 
IDKmonitor drug-tolerant anti-infliximab and anti-adalimumab anti-
body assays are lower than the manufacturer's suggested threshold 
of 10 AU/mL for both infliximab (9 AU/mL) and adalimumab (6 AU/
mL). This was done in a cohort of almost 500 anti-TNF naive indi-
viduals from the Exeter 10 000 study.
Immunogenicity was more common in infliximab than adalimum-
ab-treated patients. The new anti-drug antibody thresholds, however, 
differentially increased rates of persistent, non-clearing anti-drug 
antibodies for adalimumab-treated patients. Anti-TNF anti-drug 
antibody concentrations above the newly validated, but below the 
manufacturer's recommended positivity thresholds were associated 
with intermediate drug concentrations for adalimumab. In the PANTS 
cohort this translated to higher rates of primary non-response and 
non-remission at week 54 in adalimumab-, but not infliximab-treated 
patients.
4.2 | Interpretation
Because antibody responses are heterogeneous, there is a lack of 
standardised antibody testing material meaning that manufactur-
ers define positivity thresholds in small cohorts of healthy indi-
viduals.17,18 There are several potential explanations to account for 
why the new positivity thresholds for both anti-TNF antibody as-
says were lower than the manufacturer's recommended thresholds. 
Most importantly, our sample was more than 10 times larger than 
the manufacturer's original cohorts,24,25 meaning that we were able 
to report positivity thresholds with greater precision: in particular, 
for the anti-adalimumab assay where the prevalence, and variance 
of anti-drug antibody concentrations, were less than the anti-inflixi-
mab concentrations. Furthermore, compared to the manufacturer's 
original convenience cohorts, our selection of patients without any 
comorbidities from the Exeter 10 000 cohort were less likely to 
















Clearingb  21.1% (2678/12 683) 21.5% (2725/12 683) 0.48 8.6% (625/7272) 8.9% (644/7272) 0.60
Non-clearingc  26.7% (3390/12 683) 29.4% (3733/12 683) <0.0001 15.8% (1146/7272) 26.7% (1941/7272) <0.0001
Patients with more than one sample
Negatived  40.8% (2515/6170) 36.9% (2278/6170) <0.0001 70% (1872/2673) 53.6% (1434/2673) <0.0001
Transiente  8.8% (540/6170) 8.6% (530/6170) 0.77 6.8% (182/2673) 9.5% (255/2673) 0.0003
Single last test 
positivef 
9.1% (564/6170) 9.7% (597/6170) 0.97 6.7% (179/2673) 10.5% (280/2673) <0.0001
Persistentg  41.3% (2551/6170) 44.8% (2765/6170) <0.0001 16.5% (440/2673) 26.3% (704/2673) <0.0001
aChi-square test performed. 
bPositive anti-drug antibody result with an undetectable drug level. 
cPositive anti-drug antibody result with a detectable drug level. 
dAll anti-drug antibody tests negative. 
eA single positive anti-drug antibody test with subsequent negative test. 
fLast anti-drug antibody test positive with no subsequent anti-drug antibody measurements. 
gAt least two anti-drug antibody-positive tests. 
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have had cross-reactive anti-allotype antibodies such as rheumatoid 
factor.27,28
The reasons why we see a larger difference between the manu-
facturer's and the new positivity thresholds for the anti-adalimumab 
than anti-infliximab antibody assays are less clear. One explanation 
may relate to differences in the prevalence of pre-formed antibod-
ies to the drugs.29,30 Because of recognition of xenotopes in the 
mouse variable domains of the chimeric antibody, as a result of en-
vironmental exposure to rodents, pre-formed antibodies are more 
commonly detected by anti-infliximab than anti-adalimumab anti-
body assays.31,32
Establishing the prevalence and clinical impact of transient an-
ti-drug antibodies across studies is limited by a lack of standardised 
nomenclature and differences in type and drug-tolerance of the as-
says used.33-35 In this study, we have shown that lowering the posi-
tivity thresholds of the IDKmonitor anti-TNF antibody assays would 
not lead to a clinically meaningful increase in reporting of transient 
anti-drug antibodies. The significance of reporting a higher preva-
lence of persistent, non-clearing antibodies when lowering the pos-
itivity threshold is less clear. We recognise that there will always be 
a balance between test sensitivity and specificity; using the manu-
facturer's positivity thresholds, these were not well defined or val-
idated. We benchmarked specificity on 99% based on international 
guidelines, however, there is a potential for the newly classified 
group to be false positives. Equally, increasing test sensitivity by 
F I G U R E  3   (A and B) Bee-swarm box and whiskers plot showing 
anti-infliximab (A) and anti-adalimumab (B) antibody concentration 
plotted against drug concentration for samples received through 
the Exeter therapeutic drug monitoring service









































TA B L E  2   Anti-adalimumab antibody concentration stratified at 








<6 205/227 (90%) 140/193 (73%)
6-9 6/227 (3%) 18/193 (9%)
10-29 9/227 (4%) 15/193 (8%)
30-99 3/227 (1%) 7/193 (4%)
>99 4/227 (2%) 13/193 (7%)
F I G U R E  4   Bee-swarm box and whisker plot showing anti-drug 
antibody concentration against adalimumab concentration for 420 
samples received in the first year of the PANTS study
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reducing the positivity threshold may allow detection of true pos-
itives earlier in their development before leading to drug clearance.
In the PANTS study,3 like in other studies,34,36-38 immunogenicity 
only impacted clinical outcome if the antibodies led to drug clear-
ance. Studying the function of non-clearing antibodies is hampered 
by analytical difficulties of excluding drug from ex-vivo samples 
whilst maintaining a functional antibody product.17,18,39 Further 
work is needed to understand their natural history; for example, do 
non-clearing antibodies eventually clear drug with further matura-
tion; do they neutralize drug; or are they simply bystanders? For now, 
earlier detection of anti-drug antibodies may allow the introduction 
of an immunomodulator, or anti-TNF dose optimisation, to mitigate 
immunogenicity. Because these antibodies may be false positives or 
transient, repeat testing should occur before treatment changes.
4.3 | Limitations
The Exeter TDM cohort is a non-selected clinical referral cohort and 
although we recommend that blood sampling occurs just before the 
next dose, inevitably, some non-trough samples will have been pro-
cessed. Because anti-drug antibody assays are not completely drug 
tolerant, this is likely to bias the data by underestimation of rates of 
immunogenicity.40 This effect may be more important in adalimumab-
treated patients where TDM testing is more often ad-hoc rather than 
immediately before administration of drug. In addition, we have only 
studied the IDKmonitor assays here: users of other assays should con-
sider validating their positivity thresholds using similar methodologies. 
Finally, in the PANTS cohort, we used pragmatic definitions of remis-
sion closely aligned to routine treatment targets: we accept that our 
data would have been strengthened by endoscopic outcomes.
4.4 | Generalisability
As over 90% of participants in both the Exeter 10 000 and PANTS 
studies were white European, it is highly likely that our findings 
using the IDKmonitor anti-TNF drug-tolerant antibody assays are 
generalisable to other cohorts of white European patients with in-
flammatory bowel disease. Whether our results are generalisable to 
other ethnicities, where rates of anti-drug antibody formation are 
lower, is less certain.41,42 Furthermore, whether lower thresholds 
are clinically relevant in other immune-mediated disorders, such as 
rheumatoid arthritis, where autoantibodies frequently cross-react in 
anti-drug antibody ELISA assays, is also unknown.31 Manufacturers 
of other assays should consider validating their positivity thresholds 
using similar methodologies.
5  | CONCLUSIONS
Laboratories should independently derive antibody positivity thresh-
olds for assays they use as demonstrated here for the IDKmonitor 
drug-tolerant anti-drug antibody assays. Our findings suggest that 
lowering the positivity threshold of the anti-adalimumab antibody 
assay to 6 AU/mL may add value to the use of this test. Changing 
to the lower thresholds differentially increased the rates of persis-
tent, non-clearing antibodies to both infliximab and adalimumab. 
F I G U R E  5   (A) Stacked barchart showing proportion of 
adalimumab-treated patients in the PANTS study meeting criteria 
for predefined treatment outcomes stratified by week 14 anti-
adalimumab antibody concentration and (B) barchart showing the 
proportion of adalimumab-treated patients in the PANTS study in 
remission at week 54 stratified by week 14 antibody concentration
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Anti-drug antibody concentrations above the newly validated 
thresholds, but below the manufacturer's threshold, were associated 
with intermediate drug concentrations that were related to treat-
ment failure in adalimumab- but not infliximab-treated patients.
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